Trevi Therapeutics, Inc. Common Stock TRVI
Analyst Ratings
- Consensus
- Buy — 12 Buy · 0 Hold · 0 Sell (12 analysts)
- Avg. Price Target
- $24.08 (+30.5% upside)
Key Stats
- Today's Range
- $17.63 – $18.54
- 50-Day Range
- $13.20 – $20.22
- 52-Week Range
- $6.03 – $20.22
- Volume
- 1.39 million shs
- Average Volume
- 2.26 million shs
- Market Cap
- $2.53 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 7.86
- Price / Sales
- —
Short Interest
- Short Interest
- 0.01%
- Days to Cover
- 1.00
About Trevi Therapeutics, Inc. Common Stock
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
Related Stocks
Compare head-to-head: TRVI vs LLY·TRVI vs JNJ·TRVI vs ABBV·TRVI vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.